4-Methyl-2-(trifluoromethyl)pent-1-en-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Methyl-2-(trifluoromethyl)pent-1-en-3-one
• 英文别名: 4-methyl-2-(trifluoromethyl)pent-1-en-3-one
• 化学式: C₇H₉F₃O
• 分子量: 166.14
• InChiKey: SOKSHLGTAHIJKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USE THEREOF
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US20190209564A1

  公开（公告）日：2019-07-11

  Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R 1 , R 2 , R 3 , R 4 , ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

  提供了一种不可逆的成纤维细胞生长因子受体（FGFR）抑制剂，如式I所示，以及其药学上可接受的盐、立体异构体、药物制剂、药物组合物及其应用。R1、R2、R3、R4、环A、Ar、环B和弹头如说明书中所定义。该化合物对成纤维细胞生长因子受体具有高效和高选择性的抑制作用，可用于治疗异常FGF/FGFR介导的疾病，特别是癌症的治疗。
• INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
  申请人：Bifulco, Jr. Neil

  公开号：US20150119405A1

  公开（公告）日：2015-04-30

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

  本处描述的是FGFR-4的抑制剂，包括含有此类化合物的药物组合物，以及使用此类化合物和组合物的方法。
• KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
  申请人：AMGEN INC.

  公开号：US20180177767A1

  公开（公告）日：2018-06-28

  Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

  本文提供了KRAS G12C抑制剂，其组成，以及使用方法。这些抑制剂对治疗多种疾病有用，包括胰腺癌、结直肠癌和肺癌。
• Inhibitors of the fibroblast growth factor receptor
  申请人：BLUEPRINT MEDICINES CORPORATION

  公开号：US10000490B2

  公开（公告）日：2018-06-19

  Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of FGFR-4.

  本文描述了 FGFR-4 的抑制剂、包括此类化合物的药物组合物以及使用此类化合物和组合物抑制 FGFR-4 活性的方法。
• Inhibitors of fibroblast growth factor receptor and use thereof
  申请人：Nanjing TransThera Biosciences Co. Ltd.

  公开号：US10744139B2

  公开（公告）日：2020-08-18

  Provided are an irreversible inhibitor of a fibroblast growth factor receptor (FGFR) as indicated by formula I, a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical preparation, a pharmaceutical composition and an application thereof. R1, R2, R3, R4, ring A, Ar, ring B and warhead are as defined in the specification. The compound has high-efficiency and high-selectivity inhibition of a fibroblast growth factor receptor and can be applied to treatment of abnormal FGF/FGFR-mediated diseases, in particular the treatment of cancers.

  本发明提供了一种如式 I 所示的成纤维细胞生长因子受体（FGFR）不可逆抑制剂、一种药学上可接受的盐、一种立体异构体、一种药物制剂、一种药物组合物及其应用。R1、R2、R3、R4、环 A、Ar、环 B 和弹头如说明书中所定义。该化合物对成纤维细胞生长因子受体具有高效率和高选择性的抑制作用，可应用于治疗异常的FGF/FGFR介导的疾病，特别是癌症的治疗。